The Federal Trade Commission is challenging hundreds of pharmaceutical patent listings in an effort to smooth the path to more affordable alternatives to brand-name drugs—including blockbusters ...
But a challenge to an Orange Book patent, should a brand-name manufacturer decide to fight in court, also delays a generic’s approval for 30 months. The FTC says that drugmakers needlessly list ...
The U.S. Federal Trade Commission (FTC) is not done with its crackdown on what it views as improper listing of patents with the FDA. After an initial round of challenges launched in November ...
After the FTC’s November action, several manufacturers de-listed patents and three top drugmakers announced they would cap inhaler out-of-pocket costs at $35. “By filing bogus patent listings, pharma ...
The Federal Trade Commission is stepping up its crackdown on so-called "junk ... on," FTC Chair Lina Khan said. The agency sent letters to 10 companies, warning that their patent listings were ...
FTC’s latest action targets more than 300 Orange Book patent listings across 10 different companies, which brings the total to more than 400 patent listings across 14 companies and should send a ...
The move targets over 300 listings for 20 branded products from companies such as AstraZeneca ... Khan, chair, FTC, in a press release. “By challenging junk patent filings, the FTC is fighting these ...
Agency challenges 300-plus patent listings in FDA registry November’s ... Federal Trade Commission is targeting as it challenges more than 300 “junk patent listings” in the FDA’s registry of approved ...
《Federal Trade Commission》米国の連邦取引委員会。1914年設立の独立行政委員会。独占禁止法の実施状況の監査、反トラスト法に関する調査などを行う。